AtaiBeckley Inc. (ATAI)

In September 2025, the stock experienced a 15% surge. In October 2025, Needham initiated coverage with a "Buy" rating and a price forecast of $12, and AtaiBeckley received Breakthrough Therapy designation from the FDA for BPL-003. Also in October 2025, the company priced a secondary offering of its common stock and Zacks.com upgraded ATAI to a Zacks Rank #2 (Buy). In November 2025, H.C. Wainwright reiterated a Buy rating with a $15.00 price target. In December 2025, AtaiBeckley completed its redomiciliation to the United States, was added to the Nasdaq Biotechnology Index (NBI), and was granted a new U.S. patent for EMP-01. In January 2026, the company provided an update and outlook for 2026. In February 2026, a "Bearish Crossover" technical indicator was observed. Over the past year, ATAI's stock has seen a 72.9% return, outperforming the US Pharmaceuticals industry and the US Market; however, over the past six months, the stock has decreased by 10.24%.

AtaiBeckley Inc.'s products and services are not subject to traditional demand seasonality. Demand is driven by clinical development, regulatory milestones, and the prevalence of mental health conditions.

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders, utilizing both psychedelic and non-psychedelic compounds. The company is headquartered in Berlin, Germany, with a corporate office in New York, NY. AtaiBeckley's pipeline includes BPL-003 for treatment-resistant depression and alcohol use disorder, RL-007 for cognitive impairment associated with schizophrenia, ELE-101 for major depressive disorder, VLS-01 for treatment-resistant depression, EMP-01 for social anxiety disorder, EGX-A & EGX-B for treatment-resistant depression, COMP360 for psilocybin therapy, and GRX-917 for anxiety, depression, and neurological disorders. Atai Life Sciences merged with Beckley Psytech, forming AtaiBeckley Inc., and completed its U.S. redomiciliation in December 2025.

AtaiBeckley Inc. is headquartered in Berlin, Germany, and maintains a corporate office in New York, NY. The company conducts global clinical trials across multiple geographies, including North America and Europe. It has established banking relationships in the US and Western Europe and plans for future expansion into the Asia Pacific region.

AtaiBeckley Inc.'s brand reputation has been positively influenced by clinical advancements and strategic corporate actions. The company maintains a consensus "Strong Buy" rating from analysts. Positive clinical trial results, the FDA's Breakthrough Therapy designation for BPL-003, the merger with Beckley Psytech, the redomiciliation to the United States, and the granting of a new U.S. patent for EMP-01 have all contributed to a positive reputation. The company's focus on unmet medical needs also enhances its reputation. While a setback occurred in January 2023, the focus of the past year has been on positive developments.

Approximately 2.91% of AtaiBeckley Inc.'s stock is held by institutional investors, 23.34% by insiders, and 73.75% by public companies and individual investors. Major institutional owners and shareholders include Adage Capital Partners Gp, L.l.c., Morgan Stanley, and Citadel Advisors Llc, among others. Apeiron Investment Group Ltd. owns the most shares among individual and public company investors, and Peter Thiel is also a major investor.